The highly significant dose reductions in LDL-C (Table 2 ) were confirmed in a number of studies, including trials in FH patients [ 47 – 50 ].
1
—
—
The highly significant dose reductions in LDL-C (Table 2 ) were confirmed in a number of studies, including trials in FH patients [ 47 – 50 ].